ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$19.98 USD
+0.24 (1.22%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $20.09 +0.11 (0.55%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
Income Statements
Fiscal Year end for ADMA Biologics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 258 | 154 | 81 | 42 | 29 |
Cost Of Goods | 169 | 119 | 80 | 61 | 40 |
Gross Profit | 89 | 35 | 1 | -19 | -10 |
Selling & Adminstrative & Depr. & Amort Expenses | 67 | 75 | 60 | 46 | 31 |
Income After Depreciation & Amortization | 22 | -39 | -58 | -65 | -41 |
Non-Operating Income | -25 | -7 | 0 | 1 | 2 |
Interest Expense | 25 | 19 | 13 | 12 | 9 |
Pretax Income | -28 | -66 | -72 | -76 | -48 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -28 | -66 | -72 | -76 | -48 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -28 | -66 | -72 | -76 | -48 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 32 | -30 | -51 | -59 | -37 |
Depreciation & Amortization (Cash Flow) | 11 | 9 | 7 | 6 | 4 |
Income After Depreciation & Amortization | 22 | -39 | -58 | -65 | -41 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 223.98 | 197.88 | 139.58 | 86.15 | 54.35 |
Diluted EPS Before Non-Recurring Items | 0.00 | -0.30 | -0.51 | -0.88 | -0.92 |
Diluted Net EPS (GAAP) | -0.13 | -0.33 | -0.51 | -0.88 | -0.89 |
Fiscal Year end for ADMA Biologics Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 107.19 | 81.88 | 73.90 | 67.27 | 60.12 |
Cost Of Goods | 49.74 | 42.77 | 42.82 | 42.62 | 43.43 |
Gross Profit | 57.45 | 39.11 | 31.09 | 24.65 | 16.69 |
SG&A, R&D, and Dept/Amort Expenses | 18.25 | 17.28 | 16.86 | 15.97 | 17.16 |
Income After SG&A, R&D, and Dept/Amort Expenses | 39.20 | 21.83 | 14.23 | 8.68 | -0.47 |
Non-Operating Income | 0.43 | 0.35 | -25.66 | 0.28 | 0.40 |
Interest Expense | 3.78 | 3.77 | 6.21 | 6.40 | 6.30 |
Pretax Income | 35.85 | 18.40 | -17.64 | 2.57 | -6.37 |
Income Taxes | 3.79 | 0.60 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 32.06 | 17.81 | -17.64 | 2.57 | -6.37 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 32.06 | 17.81 | -17.64 | 2.57 | -6.37 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 242.17 | 236.41 | 225.97 | 233.76 | 222.68 |
Diluted EPS Before Non-Recurring Items | 0.13 | 0.08 | 0.04 | 0.01 | -0.02 |
Diluted Net EPS (GAAP) | 0.13 | 0.08 | -0.08 | 0.01 | -0.03 |